AdvisorShares Pure US Cannabis ETF (NY:MSOS)

4.470 -0.130 (-2.83%)

Official Closing Price Updated: 8:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AdvisorShares Pure US Cannabis ETF

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

The Florida Keys: Cannabis Legalization Brings The Sunshine State Into Focus ↗

August 17, 2024

Via Benzinga

Topics Cannabis

The Bay Street Butcher: A Cannabis ETF Rebalancing Triggers Volatility ↗

August 15, 2024

How cannabis ETF volatility impacts markets amid the MJUS rebalancing. Learn how fluctuating dynamics affect cannabis stocks.

Via Benzinga

Topics Cannabis ETFs

The Super Bowl: Cannabis Emerges As A Political Football ↗

August 12, 2024

Via Benzinga

Topics Cannabis

DEA's Call For Public Input On Cannabis Garnered 42,000 Comments: Majority Want Total Legalization Or Rescheduling ↗

July 24, 2024

Via Benzinga

Topics Cannabis

Atlas Shrugged… And the Market Rallied ↗

July 22, 2024

You’d assume the degree of uncertainty surrounding one of the most important offices in the world would ignite turmoil in the market but it hasn’t.

Via Talk Markets

The Trump Card: How Would His Second Term Treat Cannabis? ↗

July 17, 2024

Via Benzinga

Topics Government

Make America Green Again: U.S. Cannabis Has Bipartisan Support ↗

May 22, 2024

By Todd Harrison via Cannabis Confidential (May 22)

Via Benzinga

Topics Cannabis

'Opaque Political Processes,' DEA Rescheduling Deadline, And Now A New Presidential Candidate, It's No Wonder Cannabis Stocks Are Over The Place ↗

July 22, 2024

Cannabis stocks faced a mixed week with Ascend Wellness rallying on debt refinancing news, while Jushi Holdings saw a decline.

Via Benzinga

Topics Cannabis

Cannabis Stocks React To Biden Announcement: Monday's Closing Market Moves ↗

July 22, 2024

The cannabis sector witnessed significant movement today, with varied performances across key stocks and ETFs following President Joe Biden’s Sunday announcement that he will not seek re-election.

Via Benzinga

Topics Cannabis ETFs

Did Pot Just Pivot? Cannabis Preps For Possible Presidential Run ↗

July 22, 2024

Via Benzinga

Topics Cannabis

Cannabis Stocks Surge Then Plummet On News That Biden Is Bowing Out Of 2024 Presidential Race ↗

July 22, 2024

President Joe Biden's announcement that he will not seek re-election has impacted the cannabis stock market.

Via Benzinga

Topics Cannabis

Joe Biden Drops Out: What Would Happen With Cannabis Legalization Under Kamala Harris Or Donald Trump? ↗

July 21, 2024

With Joe Biden out of the presidential race and Kamala Harris likely in, we analyze what's next for cannabis legalization.

Via Benzinga

Topics Cannabis

This Is What a Top Cannabis Executive Thinks Is Going to Happen in the Industry in the Next 10 to 15 Years ↗

July 03, 2024

Many cannabis companies simply can't continue on their current paths for much longer.

Via The Motley Fool

Topics Cannabis

Zero Fees, High Hopes: WEED ETF's Strategy To Capitalize On Impending Cannabis Rescheduling ↗

July 01, 2024

Roundhill's WEED ETF drops fees to 0%, leveraging anticipated rescheduling. Discover the impact and investment opportunities in cannabis ETFs.

Via Benzinga

Topics Cannabis ETFs

Will Biden's Shaky Debate Performance Affect Cannabis Reform? How A Trump Return Could Reshape Marijuana Policy ↗

June 29, 2024

President Joe Biden's shaky debate performance this week is stirring doubts among Democrats about his viability for reelection. As doubts about the president's electability circulate, questions

Via Benzinga

Topics Cannabis Government

U.S. Dollar Soars: How Does This Threaten Your Cannabis Investments? Confidential Insights ↗

June 26, 2024

In a recent issue of "Cannabis Confidential," Todd Harrison provides a succinct analysis of the current market dynamics within the cannabis industry, particularly highlighting the performance...

Via Benzinga

Topics Cannabis

7 Cannabis Stocks to Buy Now: June 2024 ↗

June 21, 2024

Cannabis may be controversial. But it’s also proving to be one of the most profitable, with some of the top cannabis stocks to buy now.

Via InvestorPlace

Topics Cannabis

What Is The Trump Factor? Justice Dept's Impact On Cannabis Rescheduling, Stocks And Investments ↗

June 18, 2024

Equity research firm Zuanic & Associates convened a panel in mid-June featuring industry experts to dissect the ongoing cannabis rescheduling efforts in the US. They provided a comprehensive outlook on...

Via Benzinga

Topics Cannabis Government

Why The Time To Invest In U.S. Cannabis Stocks Is Right Now ↗

June 18, 2024

The U.S. cannabis market presents a significantly skewed risk-reward opportunity, particularly within the realm of multi-state operators (MSOs).

Via Benzinga

Topics Cannabis

The 3 Most Undervalued Cannabis Stocks to Buy in June 2024 ↗

June 05, 2024

Undervalued cannabis stocks may be some of the most controversial trades on the market. But they’ve also proven themselves profitable.

Via InvestorPlace

Topics Cannabis

Is Tilray Brands Preparing for a Big U.S.-Based Acquisition? ↗

May 30, 2024

Acquisitions have played a big role in Tilray Brands' strategy, and the company is still not done wheeling and dealing.

Via The Motley Fool

The 2024 Millionaire’s Club: 7 Cannabis Stocks to Buy Now ↗

May 26, 2024

One of the hottest topics of the year has been cannabis stocks to buy, especially with elections nearing. Here are seven to consider.

Via InvestorPlace

Topics Cannabis

$514M Tax Breaks Await This Marijuana Company With Rescheduling, Market Cap Set To Soar ↗

May 22, 2024

Jushi Holdings Inc. (OTC: JUSHF) is poised for substantial growth with potential adult-use cannabis legalization in Ohio and Pennsylvania as well as continuous expansion in Virginia’s medical market.

Via Benzinga

Topics Cannabis

3 Cannabis Stocks That Could Be Millionaire-Makers: May Edition ↗

May 22, 2024

Cannabis stocks to buy are surging after the DOJ proposed reclassifying marijuana, signaling a promising future.

Via InvestorPlace

Topics Cannabis

Cannabis Stocks And ETFs Surged On Marijuana Rescheduling News: WTR's Industry Report Analyzes What's Behind The Optimism ↗

May 21, 2024

DOJ proposes reclassifying cannabis to Schedule III. WTR's report highlights market gains and potential industry impacts. Read insights now!

Via Benzinga

Topics Cannabis ETFs

Cannabis Stocks Rallied After Rescheduling News, Investment Management Firm Co-Founder Discusses Impact And Next Steps ↗

May 20, 2024

Explore how DOJ's cannabis rescheduling boosts stocks and insights from Emily Paxhia on the industry's future. Read now!

Via Benzinga

Topics Cannabis

Cannabis Stocks CGC, TLRY, ACB, MSOS, CRON Pop as Justice Department Moves on Rescheduling ↗

May 16, 2024

Cannabis stocks are among the big movers investors are watching closely as a key piece of legislation is pushed forward for this sector.

Via InvestorPlace

Topics Cannabis

Weed Industry Celebrates Biden's Rescheduling Move: 'Most Monumental Cannabis Reform In Half A Century' ↗

May 16, 2024

Cannabis companies and advocates applaud President Biden's announcement to reschedule and legalize cannabis, calling it a major leap forward and opportunity to correct long-standing wrongs and improve...

Via Benzinga

Topics Cannabis

Weed Stocks Rally After Biden Makes Marijuana Reclassification Announcement ↗

May 16, 2024

Shares of marijuana growers and related companies are trading higher Thursday after President Biden announced that the Department of Justice has moved to reclassify marijuana from a Schedule I...

Via Benzinga

Topics Cannabis

Biden Announces 'Monumental' Marijuana Rescheduling, DOJ To Take Next Steps ↗

May 16, 2024

Biden announces plan to reclassify marijuana from Schedule I to III, reversing inequities and removing barriers for Americans. Cannabis stocks rise.

Via Benzinga

Topics Cannabis

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.